Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

Group 1 - Y-mAbs Therapeutics, Inc. reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of +74.07% [1] - The company posted revenues of $19.53 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.96%, although this is a decrease from year-ago revenues of $22.8 million [2] - Y-mAbs Therapeutics has surpassed consensus EPS estimates two times over the last four quarters, indicating a positive trend in performance [2] Group 2 - The stock has gained approximately 8.8% since the beginning of the year, outperforming the S&P 500's gain of 7.8% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Y-mAbs Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Group 3 - Current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $20.56 million, and for the current fiscal year, it is -$0.97 on revenues of $82.08 million [7] - The Medical - Biomedical and Genetics industry, to which Y-mAbs Therapeutics belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8]